Biogen Inc.BIIB
Buy moreBuy more on a dip to our buy price, which is under today's $251.
- 4 good· Earnings beat
- 5 to watch· Profit falling
$251.26−2.15 (−0.85%)
Price at 3:00 PM ET
After hours · opens in 17h 23mNext open: Friday, Nov 13, 9:30 AM ETNASDAQ · Healthcare · Biotechnology · Large company
The price we'd buy BIIB at comes with a free account
It also has the whole brief, the scorecard and how the call has moved.A free account gets it on three stocks you pick, plus three long research reports a month.
What would change it
Sources
- From the 10-Q for the quarter to Sep 30, reported Oct 28
- Yahoo Finance daily closes to Nov 11
Any one could move it to Keep
Next report
Shrinking
sales
Compared with the S&P 500
7 points
worse in one day
16 points
worse in five trading days
+57.5% in a yearsince Nov 11, 2025
The news behind our call
written Sep 22, 9:52 AM ETSep 22, 9:52 AM ET · 1 articles · 1 sources
RSI at 52.95 avoids an overheated reading.
What changed
From Yahoo Finance and Scheduled market snapshot
Overview
In plain numbers
- Revenue grew 2.3% from a year earlier, to $10.3B in the last twelve months.
- It keeps 24 cents of every revenue dollar as operating profit, down from 31 cents in FY 2021.
- It turned 20% of revenue into free cash flow: $2.1B in the last twelve months.
- It owes $7.8B and holds $1.3B in cash and investments, so net debt is $6.5B.
Key figures
- Revenue (TTM)
- $10.3B
- Revenue growth, 1 year
- +2.3%
- Net income
- $348M
- EPS (diluted)
- $2.34
- Gross margin
- 75.8%
- Operating margin
- 23.5%
- Return on equity
- 1.9%
- Return on capital
- 7.4%
- Debt / equity
- 0.41
- Current ratio
- 1.95
- Buyback yield
- -1.49%
Revenue by region
period ending Jun 30, 2026
- United States$3.8B · 53%
- International$3.4B · 47%
Key facts
- Company value
- $36.7B
- Price / last year's earnings
- 21.8×
- Today's range
- 250.64255.05
- Past year's range
- 161.48255.05
- Yesterday's close
- $253.40
- Swings vs the market
- 0.2×smaller